Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Silver coins fall into a piggy bank.
Stocks for Beginners

Cash Feels Safe, but This Is the TFSA Risk Investors Aren’t Pricing In

A cash-heavy TFSA can look calm for years while inflation quietly erodes what your money can actually buy.

Read more »

Canadian Dollars bills
Dividend Stocks

Want Monthly Cash Flow? This 10.6% Dividend Stock Delivers

A 10.6% yield and monthly distributions sound appealing, but investors should understand how HDIF generates that income before buying.

Read more »

person enjoys shower of confetti outside
Bank Stocks

What a Comeback for Bank of Nova Scotia (BNS)! Is the Stock a Buy Now?

Scotiabank is back! BNS stock has surged 46%. Is Canada's latest banking turnaround play still a buy?

Read more »

man is enthralled with a movie in a theater
Investing

Cineplex Stock is Up 24.5% in 6 Months: Is Now Your Chance?

Cineplex stock is rising as attendance continues to recover, box office revenues are breaking records, and the share buyback continues.

Read more »

golden sunset in crude oil refinery with pipeline system
Energy Stocks

Enbridge Is Solid, But This Stock Offers More Upside

Delve into Enbridge's impressive dividends and capital appreciation, and other energy stocks that can give better returns.

Read more »

middle-aged couple work together on laptop
Energy Stocks

What $2,000 in Canadian Dividend Stocks Could Realistically Pay You

How much can $2,000 realistically pay you in annual dividends? The answer depends on the stocks you choose.

Read more »

Canada day banner background design of flag
Dividend Stocks

Carney Wants $1 Trillion Invested in Canada: This TSX Stock Could Benefit

Carney’s $1 trillion investment push is huge, and AtkinsRéalis could be paid to design and manage the projects that make…

Read more »

diversification and asset allocation are crucial investing concepts
Tech Stocks

The Market Has Punished This Stock Enough: I’d Buy Before Sentiment Turns

Constellation stock faced a significant downturn this September. Discover why the market is reacting to leadership changes and tariffs.

Read more »